ARTICLE | Clinical News

Velphoro sucroferric oxyhydroxide regulatory update

February 16, 2015 8:00 AM UTC

Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) said in an early benefit assessment that the added benefit of Velphoro sucroferric oxyhydroxide from Vifor-Fresenius Medical Care Renal Pharma Ltd. is not proven for controlling serum phosphorus levels in adults with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis. IQWiG said the manufacturer did not provide suitable data. The oral iron-based phosphate binder is marketed in the EU and U.S. for the indication. ...